Sustained Release Excipients Global Market Report 2024

The sustained release excipients market has grown strongly in recent years. It will grow from $1.29 billion in 2023 to $1.41 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth witnessed in the historic period can be attributed to a heightened demand for controlled drug release, the prevalence of chronic diseases, emphasis on patient compliance and convenience, innovations in the pharmaceutical industry, and regulatory support for extended-release formulations.

The sustained release excipients market is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period can be attributed to the rise in the geriatric population, a heightened focus on personalized medicine, challenges related to patient adherence, an increase in complex drug formulations, advancements in disease management, and the global expansion of healthcare. Major trends expected in the forecast period include a shift towards patient-centric drug delivery, collaborative efforts for formulation development, emphasis on regulatory compliance and safety, the global expansion of drug formulation technologies, and the growing influence of biopharmaceuticals.

The anticipated growth of the sustained-release excipients market is attributed to the increasing prevalence of chronic and acute diseases. Chronic diseases are persistent conditions lasting three months or more, while acute diseases have a rapid onset and short duration. Sustained-release excipients are utilized in formulating pharmaceutical products for both chronic and acute diseases, enhancing patient adherence, maintaining consistent drug levels, reducing side effects, and improving disease management. For example, cardiovascular diseases, chronic respiratory illnesses, diabetes, and cancer are significant contributors to non-communicable disease deaths, as reported by the World Health Organization in September 2022. Additionally, tuberculosis cases increased by 4.5% in 2021, according to the Pan American Health Organization in October 2022. Hence, the rising prevalence of chronic and acute diseases is a key driver for the sustained-release excipients market.

The sustained-release excipients market is also expected to benefit from the growing demand for personalized medicine. Personalized medicine involves studying individual genes, proteins, and bodily components to provide customized care using precision medicine. Sustained-release excipients play a crucial role in this field by facilitating the development of drug formulations tailored to individual patient needs. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, accounting for approximately 34% of all newly approved therapeutic molecular entities, as reported by The Scope and Significance of Progress in 2022 by the Personalized Medicine Coalition. Therefore, the increasing demand for personalized medicine contributes to the growth of the sustained-release excipients market.

The sustained-release excipients market is witnessing a significant trend of product innovation. Major companies in this market are actively engaged in developing innovative products to enhance their market position. For instance, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, introduced Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). Prolanza, an advanced Ashwagandha root-only extract, provides continuous stress-reduction support with a unique release mechanism, allowing therapeutic effects over an extended period with a once-daily dose. This sustained-release profile was demonstrated through better relative absorption, improved bioavailability, and a longer elimination half-life compared to the control component. Manufactured from natural herbs, Prolanza has been clinically proven to be effective.

Major companies in the sustained-release excipients market are directing their efforts toward technological innovations, including direct compression solutions, to gain a competitive advantage. Direct compression is an efficient tablet manufacturing process involving the direct conversion of a blend of active pharmaceutical ingredients (APIs) and excipients into tablets without additional steps such as granulation or wet massing. For example, in October 2022, Roquette Frères, a France-based provider of plant-based ingredients, introduced PEARLITOL CR-H and PEARLITOL 200 GT for direct compression. PEARLITOL CR-H, a patented blend of mannitol and hydroxypropyl methylcellulose (HPMC), allows sustained release of APIs in direct compression formulations. PEARLITOL 200 GT, a granulated form of mannitol, enhances the flowability and tabletability of direct compression formulations.

In December 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for approximately $6.7 billion. This acquisition strengthens Pfizer's capabilities and expertise in inflammation and immunology, further advancing its ability to develop effective treatments for patients with immuno-inflammatory conditions. Arena Pharmaceuticals is a US-based producer of sustained-release drug formulations.

Major companies operating in the sustained release excipients market report are Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Ashland Global Holdings, Salix Pharmaceuticals, Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, BASF Aktiengesellschaft, International Flavors & Fragrances Inc., Croda International Plc, Gattefossé SAS, Merck KGaA, Food Machinery and Chemical Corporation, Roquette Freres, Colorcon Inc., Dow Chemical Company, Wacker Chemie AG, Evonik Industries Inc., Lubrizol Corporation, Shin-Etsu Chemical Co. Ltd., Eastman Chemical Company, Kerry Group plc, Innophos Holdings Inc., Sensient Technologies Corporation, Koninklijke DSM N.V., Ingredion Incorporated, Cargill Incorporated, Archer Daniels Midland Company, DuPont de Nemours Inc., Lonza Group.

North America was the largest region in the global sustained release excipients market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sustained release excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sustained release excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of sustained-release excipient products encompass gelatin, polymers, minerals, sugars, alcohol, and chitosan. Gelatin, a protein derived from collagen, the most abundant protein in animal connective tissues such as skin, bones, and tendons, is administered through various routes such as oral, intramuscular, subcutaneous, transdermal, vaginal, ophthalmic, intravenous, and others. Various technologies are employed, including targeted delivery, microencapsulation, the Wurster technique, transdermal delivery, implants, and coacervation.

The sustained release excipients market research report provides sustained release excipients market statistics, including sustained release excipients industry global market size, regional shares, competitors with a sustained release excipients market share, detailed sustained release excipients market segments, market trends and opportunities, and any further data you may need to thrive in the sustained release excipients industry. This sustained release excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sustained-release excipients market consists of sales of ethyl cellulose, lipid-based excipients, waxes, fatty acids, polyethylene glycol (PEG), copovidone, and osmotic agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.